Safety Assurances for Dietary Supplements

References

• Dietary Supplement Health and Education Act of 1994 (DSHEA). Public Law 103–417. October 25, 1994, (103rd Congress)
   Google Scholar
• Astin J A, Marie A, Pelletier K R, et al. A review of the incorporation of complementary and alternative medicine by mainstream physicians. Arch Intern Med 1998; 158(21)2303–2310
   PubMed Web of Science ®Google Scholar
• Astin J A. Why patients use alternative medicine: results of a national study. JAMA 1998; 279(19)1548–1553
   PubMed Web of Science ®Google Scholar
• Eisenberg D M, Davis R B, Ettner S L, et al. Trends in alternative medicine use in the United States, 1990–1997: Results of a follow-up national survey. JAMA 1998; 280(18)1569–1575
   PubMed Web of Science ®Google Scholar
• Druss B G, Rosenheck R A. Association between use of unconventional therapies and conventional medical services. JAMA 1999; 282(7)651–656
   PubMed Web of Science ®Google Scholar
• Harnack L J, Rydell S A, Stang J. Prevalence of use of herbal products by adults in the Minneapolis/St Paul, Minn, metropolitan area. Mayo Clin Proc 2001; 76(7)688–694
   PubMed Web of Science ®Google Scholar
• Basch E M, Ulbricht C E. Complementary, alternative, and integrative therapies in cancer care. Cancer: Principles & Practice of Oncology (7th edition), V T Devita, S Hellman, S A Rosenberg. Lippincott Williams and Wilkins, Philadelphia, PA 2004
   Google Scholar
• Jonas W B. Alternative medicine-learning from the past, examining the present, advancing to the future. JAMA 1998; 280(18)1616–1618
   PubMed Web of Science ®Google Scholar
• Angell M, Kassirer J P. Alternative medicine-the risks of untested and unregulated remedies. N Engl J Med 1998; 339(12)839–841
   PubMed Web of Science ®Google Scholar
• Studdert D M, Eisenberg D M, Miller F H, et al. Medical malpractice implications of alternative medicine. JAMA 1998; 280(18)1610–1615
   PubMed Web of Science ®Google Scholar
• Corbin W L, Shapiro H. Physicians want education about complementary and alternative medicine to enhance communication with their patients. Arch Intern Med 2002; 162(10)1176–1181
   PubMed Web of Science ®Google Scholar
• Kroll D J. Concerns and needs for research in herbal supplement pharma-cotherapy and safety. Journal of Herbal Pharmacotherapy 2001; 1(2)3–23
   Google Scholar
• Palmer M E, Haller C, McKinney P E, et al. Adverse events associated with dietary supplements: an observational study. Lancet 2003; 361(9352)101–106
   PubMed Web of Science ®Google Scholar
• Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355(9198)134–138
   PubMed Web of Science ®Google Scholar
• Lambrecht J, Hamilton W, Rabinovich A. A review of herb-drug interactions: documented and theoretical. US Pharmacist 2000; 25(8)1–12
   Google Scholar
• Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther 2002; 27(6)391–401
   PubMed Web of Science ®Google Scholar
• Ernst E. Possible interactions between synthetic and herbal medicinal products. Part 1: A systematic review of the indirect evidence. Perfusion 2000; 13: 4–15
   Web of Science ®Google Scholar
• Izzo A A, Ernst E. Interactions between herbal medicines and prescribed drugs: A systematic review. Drugs 2001; 61(15)2163–2175
   PubMed Web of Science ®Google Scholar
• Piscitelli S C, Burstein A H. Herb-drug interactions and confounding in clinical trials. Journal of Herbal Pharmacotherapy 2002; 2(1)23–26
   PubMedGoogle Scholar
• Hardy M L. Herb-drug interactions: An evidence-based table. Alternative Medicine Alert June, 2000; 64–69
   Google Scholar
• Rogers E A, Gough J E, Brewer K L. Are emergency department patients at risk for herb-drug interactions?. Acad Emerg Med 2001; 8(9)932–934
   PubMed Web of Science ®Google Scholar
• Ang-Lee M K, Moss J, Yuan C S. Herbal medicines and perioperative care. JAMA 2001; 286(2)208–216
   PubMed Web of Science ®Google Scholar
• Farah M H, Edwards R, Lindquist M, et al. International monitoring of adverse health effects associated with herbal medicines. Pharmacoepidemiol Drug Safety 2000; 9: 105–112
   PubMed Web of Science ®Google Scholar
• Blumenthal M, Steele E. DSHEA at five years: A review of structure-function claims. HerbalGram 1999; 47: 38–39
   Google Scholar
• Dickinson A. The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003; 139(5)385–387, Pt 1
   PubMedGoogle Scholar
• Fontanarosa P B, Rennie D, DeAngelis C D. The need for regulation of dietary supplements-lessons from ephedra. JAMA 2003; 289(12)1568–1570
   PubMed Web of Science ®Google Scholar
• Anon. Kava: first suspended, now prohibited. Prescrire Int 2003; 12(66)142
   Google Scholar
• Anon. From the Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products-United States, Germany, and Switzerland, 1999–2002. JAMA 2003; 289(1)36–37
   PubMed Web of Science ®Google Scholar
• Boon H S, Wong A H. Kava: A test case for Canada’s new approach to natural health products. CMAJ 2003; 169(11)1163–1164
   PubMed Web of Science ®Google Scholar
• Barone G W, Gurley B J, Ketel B L, et al. Drug interaction between St. John’s wort and cyclosporine. Ann Pharmacother 2000; 34(9)1013–1016
   PubMed Web of Science ®Google Scholar
• De Smet P A, Touw D J. Safety of St John’s wort (Hypericum perforatum). Lancet 2000; 355(9203)575–576
   PubMedGoogle Scholar
• Henney J. Risk of drug interactions with St. John’s wort. JAMA 2000; 283(13)1
   Google Scholar
• Jobst K A, McIntyre M, St George D, et al. Safety of St. John’s wort (Hypericum perforatum). Lancet 2000; 355(9203)575
   PubMedGoogle Scholar
• Markowitz J S, DeVane C L, Boulton D W, et al. Effect of St. John’s wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000; 66(9)L133–L139
   PubMedGoogle Scholar
• Piscitelli S C, Burstein A H, Chaitt D, et al. Indinavir concentrations and St. John’s wort. Lancet 2000; 355(9203)547–548
   PubMed Web of Science ®Google Scholar
• Roby C A, Anderson G D, Kantor E, et al. St. John’s wort: Effect on CYP3A4 activity. Clin Pharmacol Ther 2000; 67(5)451–457
   PubMed Web of Science ®Google Scholar
• Ruschitzka F, Meier P J, Turina M, et al. Acute heart transplant rejection due to Saint John’s wort. Lancet 2000; 355(9203)548–549
   PubMed Web of Science ®Google Scholar
• Yuan C S, Wei G, Dey L, et al. Brief communication: American ginseng reduces warfarin’s effect in healthy patients: a randomized, controlled Trial. Ann Intern Med 2004; 141(1)23–27
   PubMed Web of Science ®Google Scholar
• Janetzky K, Morreale A P. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 1997; 54(6)692–693
   PubMed Web of Science ®Google Scholar
• Benjamin J, Muir T, Briggs K, et al. A case of cerebral haemorrhage-can Ginkgo biloba be implicated?. Postgrad Med J 2001; 77(904)112–113
   PubMed Web of Science ®Google Scholar
• Kim Y S, Pyo M K, Park K M, et al. Antiplatelet and antithrombotic effects of a combination of ticlopidine and Ginkgo biloba ext (EGb 761). Thromb Res 1998; 91(1)33–38
   PubMed Web of Science ®Google Scholar
• Matthews M K, Jr. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998; 50(6)1933–1934
   PubMed Web of Science ®Google Scholar
• Skogh M. Extracts of Ginkgo biloba and bleeding or haemorrhage. Lancet 1998; 352(9134)1145–1146
   PubMed Web of Science ®Google Scholar
• Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet 1998; 352(9121)36
   PubMed Web of Science ®Google Scholar
• Rowin J, Lewis S L. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996; 46(6)1775–1776
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration Center for Food Safety and Applied Nutrition. Online letter announcing closure of Special Nutritional Adverse Event Monitoring System. August 29, 2004, http://vm.cfsan.fda.gov/~dms/aems.html (last accessed July 15, 2004).
   Google Scholar
• Litovitz T L, Klein-Schwartz W, Rodgers G C, Jr., et al. 2001 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2002; 20(5)391–452
   PubMed Web of Science ®Google Scholar
• Charatan F. Ephedra supplement may have contributed to sportsman’s death. BMJ 2003; 326(7387)464
   PubMed Web of Science ®Google Scholar
• Shekelle P, Morton S, Maglione M, et al. Ephedra and Ephedrine for Weight Loss and Athletic Performance Enhancement: Clinical Efficacy and Side Effects. Evidence Report/Technology Assessment No. 76, Agency for Healthcare Research and Quality, Rockville, MD February, 2003, (Prepared by Southern California Evidence-based Practice Center, RAND, under Contract No 290–97–0001, Task Order No. 9)
   Google Scholar
• Shekelle P G, Hardy M L, Morton S C, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: A meta-analysis. JAMA 2003; 289(12)1537–1545
   PubMed Web of Science ®Google Scholar
• Bent S, Tiedt T N, Odden M C, et al. The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003; 138(6)468–471
   PubMed Web of Science ®Google Scholar
• Kingston R L, Borron S W. The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003; 139(5)385–387, Pt 1
   PubMedGoogle Scholar
• Dickinson A. The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003; 139(5)385–387, Pt 1
   PubMedGoogle Scholar
• Whitaker J M. The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003; 139(5)385–387, Pt 1
   PubMedGoogle Scholar
• Kimmel S E. The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003; 139(3)234
   PubMed Web of Science ®Google Scholar
• Kalman D S, Antonio J, Kreider R B. The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003; 138(12)1006–1007
   PubMed Web of Science ®Google Scholar
• Stafford N. Germany may ban kava kava herbal supplement. Reuter’s News Service Germany November 19, 2001
   Google Scholar
• Mills E, Singh R, Ross C, et al. Sale of kava extract in some health food stores. CMAJ 2003; 169(11)1158–1159
   PubMed Web of Science ®Google Scholar
• Schulze J, Raasch W, Siegers C P. Toxicity of kava pyrones, drug safety and pre-cautions-a case study. Phytomedicine 2003; 10(Suppl 4)68–73
   PubMedGoogle Scholar
• Ernst E. [Recall of the herbal anxiolytic kava. Underestimation of its value or overestimation of its risks?]. MMW Fortschr Med 2002; 144(41)40
   PubMedGoogle Scholar
• Bujanda L, Palacios A, Silvarino R, et al. Kava-induced acute icteric hepatitis. Gastroenterol Hepatol 2002; 25(6)434–435
   PubMedGoogle Scholar
• Humberston C L, Akhtar J, Krenzelok E P. Acute hepatitis induced by kava kava. J Toxicol Clin Toxicol 2003; 41(2)109–113
   PubMed Web of Science ®Google Scholar
• Stickel F, Baumuller H M, Seitz K, et al. Hepatitis induced by kava (Piper methysticum rhizoma). J Hepatol 2003; 39(1)62–67
   PubMed Web of Science ®Google Scholar
• Escher M, Desmeules J, Giostra E, et al. Hepatitis associated with kava, a herbal remedy for anxiety. BMJ 2001; 322(7279)139
   PubMed Web of Science ®Google Scholar
• Kraft M, Spahn T W, Menzel J, et al. [Fulminant liver failure after administration of the herbal antidepressant Kava-Kava]. Dtsch Med Wochenschr 2001; 126(36)970–972
   PubMed Web of Science ®Google Scholar
• Thomsen M, Vitetta L, Schmidt M, et al. Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust 2004; 180(4)198–199
   PubMed Web of Science ®Google Scholar
• Gow P J, Connelly N J, Hill R L, et al. Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust 2003; 178(9)442–443
   PubMed Web of Science ®Google Scholar
• Anon. Relevant hepatotoxic effects of kava still need to be proven. A statement of the Society for Medicinal Plant Research. Planta Med 2003; 69(11)971–972
   PubMed Web of Science ®Google Scholar
• Denham A, McIntyre M, Whitehouse J. Kava-the unfolding story: Report on a work-in-progress. J Altern Complement Med 2002; 8(3)237–263
   PubMed Web of Science ®Google Scholar
• Parkman C A. Another FDA warning: Kava supplements. Case Manager 2002; 13(4)26–28
   PubMedGoogle Scholar
• Center for Food Safety and Applied Nutrition (US Food and Drug Administration). Kava-containing dietary supplements may be associated with severe liver injury, (document issued March 25, 2002)
   Google Scholar
• Center for Food Safety and Applied Nutrition (US Food and Drug Administration). Letter to health care professionals: FDA issues consumer advisory that kava products may be associated with severe liver injury (document issued March 25, 2002), contact information for FDA Medwatch program: 1–800–332–1088
   Google Scholar
• Tubert-Bitter P, Begaud B, Moride Y, et al. Comparing the toxicity of two drugs in the framework of spontaneous reporting: A confidence interval approach. J Clin Epidemiol 1996; 49(1)121–123
   PubMed Web of Science ®Google Scholar